Literature DB >> 10494036

HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.

B Berkhout1.   

Abstract

The human immunodeficiency virus (HIV-1) has evolved into a viral quasispecies with a high replication capacity or fitness. Antiretroviral drugs potently inhibit replication of the wild-type virus, but HIV-1 responds by selection of drug-resistant variants. Here we review, in brief, the evolution of resistance to protease inhibitors that is characterized by severe fitness losses and an abundance of subsequent repair strategies. The possibility to restrict HIV-1 fitness is discussed in relation to the control of HIV-1 pathogenesis.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10494036     DOI： 10.1007/BF02253518

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN： 1021-7770            Impact factor:   8.410


  16 in total

Review 1.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

2.  Compensatory mutations restore fitness during the evolution of dihydrofolate reductase.

Authors:  Kyle M Brown; Marna S Costanzo; Wenxin Xu; Scott Roy; Elena R Lozovsky; Daniel L Hartl
Journal:  Mol Biol Evol       Date:  2010-06-24       Impact factor: 16.240

3.  Contingent neutrality in competing viral populations.

Authors:  J Quer; C L Hershey; E Domingo; J J Holland; I S Novella
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Accessible mutational trajectories for the evolution of pyrimethamine resistance in the malaria parasite Plasmodium vivax.

Authors:  Pan-Pan Jiang; Russell B Corbett-Detig; Daniel L Hartl; Elena R Lozovsky
Journal:  J Mol Evol       Date:  2013-09-27       Impact factor: 2.395

5.  Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.

Authors:  Wendy Maury; Robert J Thompson; Quentin Jones; Sarahann Bradley; Tara Denke; Prasith Baccam; Matthew Smazik; J Lindsay Oaks
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Wataru Sugiura; Zene Matsuda; Yoshiyuki Yokomaku; Kurt Hertogs; Brendan Larder; Tsuyoshi Oishi; Aiko Okano; Teiichirou Shiino; Masashi Tatsumi; Masakazu Matsuda; Hanae Abumi; Noboru Takata; Satoshi Shirahata; Kaneo Yamada; Hiroshi Yoshikura; Yoshiyuki Nagai
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Authors:  Miguel E Quiñones-Mateu; Mahlet Tadele; Mariona Parera; Antonio Mas; Jan Weber; Héctor R Rangel; Bikram Chakraborty; Bonaventura Clotet; Esteban Domingo; Luis Menéndez-Arias; Miguel A Martínez
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Developing novel oncolytic adenoviruses through bioselection.

Authors:  Wen Yan; Galila Kitzes; Farid Dormishian; Lynda Hawkins; Adam Sampson-Johannes; Josh Watanabe; Jenny Holt; Vivian Lee; Thomas Dubensky; Ali Fattaey; Terry Hermiston; Allan Balmain; Yuqiao Shen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.

Authors:  Jason D Barbour; Terri Wrin; Robert M Grant; Jeffrey N Martin; Mark R Segal; Christos J Petropoulos; Steven G Deeks
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  Interrelationship between HIV-1 fitness and mutation rate.

Authors:  Michael J Dapp; Richard H Heineman; Louis M Mansky
Journal:  J Mol Biol       Date:  2012-10-16       Impact factor: 5.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.